Kiora Q2 2026 net loss $2.1M; cash $16.8M; ABACUS-2 higher-dose enrollment underway

KIORA PHARMACEUTICALS INC

2026-Q2 EPS reported -$0.87

Net loss $2.1M vs $2.2M YoY; R&D expense $2.1M net of $1.3M Théa reimbursement; G&A flat at $1.4M.
Cash and short-term investments $16.8M at June 30, up from $13.9M at March 31; runway into late 2028.
Private placement secured for up to $24M gross, $5M upfront, remainder contingent on milestone-based warrant exercise.
ABACUS-2 Phase 2 (KIO-301) enrolling higher 100 µg dose cohort; last patient first visit Q1 2027, topline Q3 2027.
KIO-104 KLARITY Phase 2 enrolling higher-dose cohort; initial clinical data expected late 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.